Table 3.
Treatment history of patients with AS (N = 78)
| Characteristic | Patients with AS (N = 78) |
|---|---|
| Received treatment prior to secukinumab, n (%) | 78 (100.0) |
| Time since initiation of first treatment to initiation of secukinumab, median (IQR), months | 18.1 (9.0–33.1) |
| No. of treatments received prior to secukinumaba | |
| Mean (SD) | 2.5 (1.3) |
| 1, n (%) | 16 (20.5) |
| 2, n (%) | 32 (41.0) |
| ≥ 3, n (%) | 30 (38.5) |
| No. of biologics received prior to secukinumaba | |
| Mean (SD) | 0.8 (0.7) |
| 1, n (%) | 42 (53.8) |
| 2, n (%) | 8 (10.3) |
| ≥ 3, n (%) | 1 (1.3) |
| Treatments directly preceding secukinumab, n (%)b | |
| NSAIDs | 41 (52.6) |
| Any biologic | 40 (51.3) |
| Nonbiologic DMARDs | 22 (28.2) |
| Analgesics and opioids | 6 (7.7) |
| Glucocorticoids | 5 (6.4) |
AS ankylosing spondylitis, DMARD disease-modifying antirheumatic drug, IQR interquartile range, NSAID nonsteroidal anti-inflammatory drug
aThe number of treatments received prior to secukinumab was calculated among patients who had received ≥ 1 treatment prior to secukinumab. The number of all previous distinct treatments was considered, regardless of treatment combinations
bMultiple treatments directly preceding secukinumab could be selected for each patient